Here are two conflicting narratives about the virus. With three vaccine candidates out with a first look at efficacy data, Wall Street is more optimistic about the light at the end of the pandemic tunnel. SVB Leerink analysts upgraded outlooks for Pfizer (PFE), BioNTech (BNTX), Moderna (MRNA) and AstraZeneca (AZN) Tuesday, pointing to the long-term protection that is likely to come from the various candidates. While health experts are still wary to commit to the durability outlook, analyst Geoffrey Porges said in a note Tuesday, “We now believe that immunity after natural infection will be virtually lifelong and expect recovered COVID cases to need only a single boosting immunization a year or two after their infection to be protected against re-infection for life (similar to immunity after measles or other respiratory pathogens apart from influenza).” Porges said that takes needing annual vaccines off the table, likely requiring one additional vaccination in a lifetime. “We failed to realize that it’s not like influenza, but more like measles, mumps and rubella,” Porges said. This is huge folks because some people were not going to get a shot every year... I know I wasn't. That is big news. The Other thing though I heard a scientist on the radio say we are going to always get coronavirus virus's now and that in a future year it will be Covid 27 or Covid 30 there will always be a new one so a Universal Covid vaccine is tops and that too is in the works... Who will produce the Universal Covid vaccine?.... Might That Be An investment?<----- & might that be the one to take.~
Preventing the Next Pandemic by LaTina Emerson Science is usually a marathon,not a sprint. But with a new, deadly virus wreaking havoc on the world, researchers are working at a breakneck pace to develop an effective vaccine for SARS-CoV-2, one of seven known human coronaviruses, that could end the pandemic and help us regain some sense of normalcy. There are at least 200 experimental vaccines in various stages of development, and scientists are taking countless approaches. One of the biggest challenges in developing an effective vaccine against SARS-CoV-2 is the virus’s propensity to mutate. The novel coronavirus is what’s known as an RNA virus, meaning its genetic code uses RNA, not DNA, and these viruses are known for quickly evolving and mutating into new strains. Studies already reveal SARS-CoV-2 has mutated into at least 10 different genetic variants around the world, and even if a coronavirus vaccine is developed in the next few months, it may only be effective against the strain or strains that were used in the initial trials. This propensity for mutation is why seasonal vaccines against the flu, another RNA virus, are often ineffective. Each year in February, six months before flu season starts, the World Health Organization holds a meeting with scientists to forecast which strains of the virus are most likely to circulate later that year. (They make their determination so early to give manufacturers the time they need to produce hundreds of millions of doses.) By the time the new doses are distributed, though, the circulating flu strains may have changed their pattern or accumulated enough mutations reduce the effectiveness of the vaccine. As a result, the effectiveness of seasonal flu vaccines ranges between just 19 and 60 percent each year, according to the Centers for Disease Control and Prevention. It’s also why you can still get the flu year after year. You might develop immunity against a viral protein one year, but by next flu season the protein would have rapidly changed. Baozhong Wang, a professor in the Institute for Biomedical Sciences at Georgia State, is taking a broader approach to fighting SARS-CoV-2 using an innovative strategy he created through his research on the flu. He’s working to develop a universal vaccine that could protect against any variants of the novel coronavirus and other genetically similar coronaviruses. “Few researchers are focused on a broadly protective coronavirus vaccine,” Wang says. “Yet given the severity of the disease and the ever-mutating RNA genome of SARS-CoV-2, a broadly protective vaccine is the ultimate countermeasure against the pandemic.” Coronaviruses are named after the spiky proteinsthat ring their surface like a crown (the word “corona” means “crown” in Latin). SARS-CoV-2 uses its spike proteins to lock onto the surface of human cells and invade them. Once the virus is inside a human cell, it hijacks it, essentially turning the cell into a virus-producing factory. Zeroing in on these spike proteins is the key to making an effective vaccine. In his work on the flu, which is funded by the National Institutes of Health, Wang has targeted an interior part of the virus’ surface protein that is commonly shared among influenza viruses. (Seasonal flu vaccines target the protein’s exterior head, which varies widely from strain to strain.) These vaccines have shown great potential in inducing broad immune responses, protecting the recipient against all flu viruses. He hypothesizes that using the same approach — targeting commonly shared antigens from coronavirus spike proteins — will induce the same type of broadly protective immune responses against SARS-CoV-2, any mutations of the virus and other closely related coronavirus strains. To be successful, though, a universal vaccine needs to stimulate the body’s immune system without triggering an overactive inflammatory response that can damage healthy tissue. This balance is particularly delicate given that many COVID-19 patients die from a severe overreaction of the immune system’s inflammatory response known as a “cytokine storm.”
US Auto Parts Network call volume above normal and directionally bullish 14:25 PRTS Bullish option flow detected in US Auto Parts Network with 11,259 calls trading, 3x expected, and implied vol increasing almost 11 points to 108.22%. Dec-20 10 calls and Dec-20 17.5 calls are the most active options, with total volume in those strikes near 7,000 contracts. The Put/Call Ratio is 0.05. Earnings are expected on March 9th. Show Related Items >> PRTS I'm 90% sure this was a stock I saw pushed today on TV and sounded interesting... I wrote it on an envelope my wife moved... very hot sector low price this looks tastsy!
ADDING CARPARTS.COM TO THE IDEAS FOR NOW PORTFOLIO!!!!-500 SHARES!! OMG I DID IT. I FOUND SOMETHING GOOD. HEARD A GOOD THING ABOUT THIS FORGOT IT LOST AN ENVELOPE BUT THE MIND CAME BACK THIS IS A PLAY ON CAR USAGE THIS IS THE NEW BUY!!!! CarParts.com re-initiated with a Buy at Roth Capital 09/09 PRTS Roth Capital analyst Darren Aftahi re-initiated coverage of CarParts.com with a Buy rating and $17 price target. The analyst views the company as a "pure-play auto parts platform with a turnaround growth story." Macro tailwinds, including accelerated e-commerce adoption and limited penetration, along with an expanding distribution footprint, new management team, and website revamp are catalysts for CarParts.com, Aftahi tells investors in a research note. The analyst believes the company "helps fill the void" for low-cost online auto parts in a growing shift towards online commerce. $14.50 PRTS **
Sector wise this is a tough time now. Big tech sleeping and other tech looking pretty bad but I wanted some heft something to do with cars and we have found that. I'm sure Carvana is going to rip as well but so expensive to buy. Here we have .com and we have a non AMZN area....
CarParts.com, Inc. (PRTS) NasdaqGS - NasdaqGS Real Time Price. $14.70+1.20 (+8.89%)<------- As of 3:07PM EST.